{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T05:59:53Z","timestamp":1772085593532,"version":"3.50.1"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T00:00:00Z","timestamp":1541721600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s11864-018-0582-5","type":"journal-article","created":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T02:27:18Z","timestamp":1541730438000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Novel Surgical Strategies in the Treatment of Gynecological Malignancies"],"prefix":"10.1007","volume":"19","author":[{"given":"Martina Aida","family":"Angeles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Mart\u00ednez-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Migliorelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Voglimacci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justine","family":"Figurelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Motton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yann","family":"Tanguy Le Gac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gw\u00e9na\u00ebl","family":"Ferron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandra","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,9]]},"reference":[{"key":"582_CR1","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1097\/IGC.0000000000001216","volume":"28","author":"D Cibula","year":"2018","unstructured":"Cibula D, P\u00f6tter R, Planchamp F, Avall-Lundqvist E, Fischerova D, Haie Meder C, et al. The European Society of Gynecological Oncology\/European Society for Radiotherapy and Oncology\/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer. Int J Gynecol Cancer. 2018;28:641\u201355.","journal-title":"Int J Gynecol Cancer"},{"key":"582_CR2","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1200\/JCO.2007.13.8933","volume":"26","author":"C Altgassen","year":"2008","unstructured":"Altgassen C, Hertel H, Brandst\u00e4dt A, K\u00f6hler C, D\u00fcrst M, Schneider A. Multicenter validation study of the sentinel lymph node concept in cervical cancer: AGO study group. J Clin Oncol. 2008;26:2943\u201351.","journal-title":"J Clin Oncol"},{"key":"582_CR3","unstructured":"Frumovitz M, Plante M, Lee PS, Sandadi S, Lilja JF, Escobar PF, et al. The FILM Trial: a randomized phase III multicenter study assessing near infrared fluorescence in the identification of sentinel lymph nodes (SLN). Gynecol Oncol. Elsevier Inc. 2018;149:7."},{"key":"582_CR4","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1200\/JCO.2010.32.0432","volume":"29","author":"F L\u00e9curu","year":"2011","unstructured":"L\u00e9curu F, Mathevet P, Querleu D, Leblanc E, Morice P, Dara\u00ef E, et al. Bilateral negative sentinel nodes accurately predict absence of lymph node metastasis in early cervical cancer: results of the SENTICOL study. J Clin Oncol. 2011;29:1686\u201391.","journal-title":"J Clin Oncol"},{"key":"582_CR5","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1245\/s10434-012-2597-7","volume":"20","author":"AS Bats","year":"2013","unstructured":"Bats AS, Mathevet P, Buenerd A, Orliaguet I, Mery E, Zerdoud S, et al. The sentinel node technique detects unexpected drainage pathways and allows nodal ultrastaging in early cervical cancer: insights from the multicenter prospective SENTICOL study. Ann Surg Oncol. 2013;20:413\u201322.","journal-title":"Ann Surg Oncol"},{"key":"582_CR6","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Mathevet P, Lecuru F, Magaud L, Bouttitie F. Sentinel lymph node biopsy for early cervical cancer: results of a randomized prospective, multicenter study (Senticol 2) comparing adding pelvic lymph node dissection vs sentinel node biopsy only. Gynecol Oncol. Elsevier Inc. 2017;145:2\u20133. Randomized trial comparing SNLD vs pelvic lymphadenectomy in early cervical cancer.","DOI":"10.1016\/j.ygyno.2017.03.029"},{"key":"582_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ygyno.2007.03.026","volume":"106","author":"NR Abu-Rustum","year":"2007","unstructured":"Abu-Rustum NR, Barakat RR. Observations on the role of circumflex iliac node resection and the etiology of lower extremity lymphedema following pelvic lymphadenectomy for gynecologic malignancy. Gynecol Oncol. 2007;106:4\u20135.","journal-title":"Gynecol Oncol"},{"key":"582_CR8","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Querleu D, Cibula D, Abu-Rustum NR. Update on the Querleu\u2013Morrow Classification of radical hysterectomy. Ann Surg Oncol. Springer International Publishing. 2017;24:3406\u201312. World referent classification for radical hysterectomy.","DOI":"10.1245\/s10434-017-6031-z"},{"key":"582_CR9","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ygyno.2013.09.004","volume":"132","author":"PT Ramirez","year":"2014","unstructured":"Ramirez PT, Pareja R, Rend\u00f3n GJ, Millan C, Frumovitz M, Schmeler KM. Management of low-risk early-stage cervical cancer: should conization, simple trachelectomy, or simple hysterectomy replace radical surgery as the new standard of care? Gynecol Oncol. 2014;132:254\u20139.","journal-title":"Gynecol Oncol"},{"key":"582_CR10","unstructured":"Pareja R, Rend\u00f3n GJ, Vasquez M, Echeverri L, Sanz-Lomana CM, Ramirez PT. Immediate radical trachelectomy versus neoadjuvant chemotherapy followed by conservative surgery for patients with stage IB1 cervical cancer with tumors 2\u00a0cm or larger: a literature review and analysis of oncological and obstetrical outcomes. Gynecol Oncol. Elsevier Inc. 2015;137:574\u201380."},{"key":"582_CR11","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Bentivegna E, Gouy S, Maulard A, Chargari C, Leary A, Morice P, et al. Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review. Lancet Oncol. 2016;17:e240\u201353. Elsevier Ltd. Deep and meticulous review for conservative management of cervical cancer.","DOI":"10.1016\/S1470-2045(16)30032-8"},{"key":"582_CR12","unstructured":"Pareja FR, Ramirez PT, Borrero FM, Angel CG. Abdominal radical trachelectomy for invasive cervical cancer: a case series and literature review. Gynecol Oncol. Elsevier BV. 2008;111:555\u201360."},{"key":"582_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jmig.2016.06.004","volume":"24","author":"C Martel-Billard","year":"2017","unstructured":"Martel-Billard C, Faller E, Delaine M, Boisram\u00e9 T, Baldauf JJ, Akladios CY. Type B laparoscopic radical trachelectomy with pelvic lymphadenectomy for early cervical cancer. J Minim Invasive Gynecol. 2017;24:14\u20135.","journal-title":"J Minim Invasive Gynecol"},{"key":"582_CR14","doi-asserted-by":"publisher","unstructured":"Ramirez PT, Schmeler KM, Malpica A, Soliman PT. Safety and feasibility of robotic radical trachelectomy in patients with early-stage cervical cancer. Gynecol Oncol. Elsevier Inc. 2010;116:512\u20135. \n                      https:\/\/doi.org\/10.1016\/j.ygyno.2009.10.063\n                      \n                    .","DOI":"10.1016\/j.ygyno.2009.10.063"},{"key":"582_CR15","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/GRF.0000000000000286","volume":"60","author":"KI Stewart","year":"2017","unstructured":"Stewart KI, Fader AN. New developments in minimally invasive gynecologic oncology surgery. Clin Obstet Gynecol. 2017;60:330\u201348.","journal-title":"Clin Obstet Gynecol"},{"key":"582_CR16","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Zhou WY, Deng L, Cheng XH, Zhang Y, Qing LZ. Laparoscopy versus laparotomy for the management of early stage cervical cancer. BMC Cancer. 2015;15:928. \n                      https:\/\/doi.org\/10.1186\/s12885-015-1818-4\n                      \n                     Largest review of retrospective studies comparing minimally invasive surgery versus laparotomy for early cervical cancer.","DOI":"10.1186\/s12885-015-1818-4"},{"key":"582_CR17","doi-asserted-by":"publisher","unstructured":"Shazly SAM, Murad MH, Dowdy SC, Gostout BS, Famuyide AO. Robotic radical hysterectomy in early stage cervical cancer: a systematic review and meta-analysis. Gynecol Oncol. Elsevier Inc. 2015;138:457\u201371. \n                      https:\/\/doi.org\/10.1016\/j.ygyno.2015.06.009\n                      \n                    .","DOI":"10.1016\/j.ygyno.2015.06.009"},{"key":"582_CR18","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Ramirez PT, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R. Phase III randomized trial of laparoscopic or robotic versus abdominal radical hysterectomy in patients with early- stage cervical cancer: LACC Trial. 49th Annu Meet Soc Gynecol Oncol March. 2018;2\u20135. Preliminary results of LACC trial showing worse oncological outcomes in minimally invasive surgery versus laparotomy for early cervical cancer.","DOI":"10.1016\/j.ygyno.2018.04.552"},{"key":"582_CR19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/IGC.0000000000000588","volume":"26","author":"E Leblanc","year":"2016","unstructured":"\u2022 Leblanc E, Katdare N, Narducci F, Bresson L, Gouy S, Morice P, et al. Should systematic infrarenal para-aortic dissection be the rule in the pretherapeutic staging of primary or recurrent locally advanced cervix cancer patients with a negative preoperative para-aortic PET imaging? Int J Gynecol Cancer. 2016;26:169\u201375 Retrospective study that shows inframesenteric lymph node dissection as a valid option for staging in locally advanced cervical cancer.","journal-title":"Int J Gynecol Cancer"},{"key":"582_CR20","doi-asserted-by":"publisher","unstructured":"Gouy S, Morice P, Narducci F, Uzan C, Gilmore J, Kolesnikov-Gauthier H, et al. N0odal-staging surgery for locally advanced cervical cancer in the era of PET. Lancet Oncol. Elsevier Ltd. 2012;13:e212\u201320. \n                      https:\/\/doi.org\/10.1016\/S1470-2045(12)70011-6\n                      \n                    .","DOI":"10.1016\/S1470-2045(12)70011-6"},{"key":"582_CR21","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.1200\/JCO.2012.47.3520","volume":"31","author":"S Gouy","year":"2013","unstructured":"Gouy S, Morice P, Narducci F, Uzan C, Martinez A, Rey A, et al. Prospective multicenter study evaluating the survival of patients with locally advanced cervical cancer undergoing laparoscopic para-aortic lymphadenectomy before chemoradiotherapy in the era of positron emission tomography imaging. J Clin Oncol. 2013;31:3026\u201333.","journal-title":"J Clin Oncol"},{"key":"582_CR22","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1002\/cncr.23400","volume":"112","author":"MA Gold","year":"2008","unstructured":"Gold MA, Tian C, Whitney CW, Rose PG, Lanciano R, Mackey D. Surgical versus radiographic determination of para-aortic lymph node metastases before chemoradiation for locally advanced cervical carcinoma: a gynecologic oncology group study. Cancer. 2008;112:1954\u201363.","journal-title":"Cancer"},{"key":"582_CR23","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S0090-8258(03)00064-7","volume":"89","author":"CH Lai","year":"2003","unstructured":"Lai CH, Huang KG, Hong JH, Lee CL, Chou HH, Chang TC, et al. Randomized trial of surgical staging (extraperitoneal or laparoscopic) versus clinical staging in locally advanced cervical cancer. Gynecol Oncol. 2003;89:160\u20137.","journal-title":"Gynecol Oncol"},{"key":"582_CR24","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1111\/1471-0528.14492","volume":"124","author":"C Pomel","year":"2017","unstructured":"\u2022 Pomel C, Martinez A, Bourgin C, Beguinot M, Benoit C, Naik R, et al. Survival effect of laparoscopic para-aortic staging in locally advanced cervical cancer: a retrospective cohort analysis. BJOG An Int J Obstet Gynaecol. 2017;124:1089\u201394 Retrospective study that questions the benefit of paraaortic surgical staging in locally advanced cervical cancer.","journal-title":"BJOG An Int J Obstet Gynaecol"},{"key":"582_CR25","doi-asserted-by":"crossref","unstructured":"H\u00f6ckel M. Long-term experience with (laterally) extended endopelvic resection (LEER) in relapsed pelvic malignancies. Curr Oncol Rep. 2015;17.","DOI":"10.1007\/s11912-014-0435-8"},{"key":"582_CR26","unstructured":"Ferron G, Gangloff D, Querleu D, Frigenza M, Torrent JJ, Picaud L, et al. Vaginal reconstruction with pedicled vertical deep inferior epigastric perforator flap (diep) after pelvic exenteration. A consecutive case series. Gynecol Oncol. Elsevier B.V. 2015;138:603\u20138."},{"key":"582_CR27","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1097\/PRS.0b013e3182a97ea2","volume":"132","author":"SS Qiu","year":"2013","unstructured":"Qiu SS, Jurado M, Hontanilla B. Comparison of TRAM versus DIEP flap in total vaginal reconstruction after pelvic exenteration. Plast Reconstr Surg. 2013;132:1020\u20137.","journal-title":"Plast Reconstr Surg"},{"key":"582_CR28","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1245\/s10434-017-6120-z","volume":"25","author":"A Martinez","year":"2018","unstructured":"Martinez A, Filleron T, Rouanet P, M\u00e9eus P, Lambaudie E, Classe JM, et al. Prospective assessment of first-year quality of life after pelvic exenteration for gynecologic malignancy: a French multicentric study. Ann Surg Oncol. 2018;25:535\u201341.","journal-title":"Ann Surg Oncol"},{"key":"582_CR29","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/IGC.0b013e3181a1303e","volume":"19","author":"G Ferron","year":"2009","unstructured":"Ferron G, Lim TYK, Pomel C, Soulie M, Querleu D. Creation of the Miami pouch during laparoscopic-assisted pelvic exenteration the initial experience. Int J Gynecol Cancer. 2009;19:466\u201370.","journal-title":"Int J Gynecol Cancer"},{"key":"582_CR30","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.ygyno.2004.01.021","volume":"93","author":"C Pomel","year":"2004","unstructured":"Pomel C, Castaigne D. Laparoscopic hand-assisted Miami Pouch following laparoscopic anterior pelvic exenteration. Gynecol Oncol. 2004;93:543\u20135.","journal-title":"Gynecol Oncol"},{"key":"582_CR31","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.gyobfe.2011.07.021","volume":"39","author":"C Jauffret","year":"2011","unstructured":"Jauffret C, Lambaudie E, Bannier M, Buttarelli M, Houvenaeghel G. Place de la c\u0153lioscopie robot-assist\u00e9e dans la prise en charge des r\u00e9cidives de cancers pelviens. Gynecol Obstet Fertil. 2011;39:674\u201380.","journal-title":"Gynecol Obstet Fertil"},{"key":"582_CR32","doi-asserted-by":"publisher","unstructured":"Chiva LM, Lapuente F, N\u00fa\u00f1ez C, Ram\u00edrez PT. Ileal orthotopic neobladder after pelvic exenteration for cervical cancer. Gynecol Oncol. Elsevier Inc. 2009;113:47\u201351. \n                      https:\/\/doi.org\/10.1016\/j.ygyno.2008.12.020\n                      \n                    .","DOI":"10.1016\/j.ygyno.2008.12.020"},{"key":"582_CR33","doi-asserted-by":"publisher","unstructured":"Querleu D, Darai E, Lecuru F, Rafii A, Chereau E, Collinet P, et al. Prise en charge primaire des cancers de l\u2019endom\u00e8tre: recommandations SFOG-CNGOF. Gynecol Obstet Fertil Senol. Elsevier Masson SAS. 2017;45:715\u201325. \n                      https:\/\/doi.org\/10.1016\/j.gofs.2017.10.008\n                      \n                    .","DOI":"10.1016\/j.gofs.2017.10.008"},{"key":"582_CR34","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1001\/jama.2017.2068","volume":"317","author":"M Janda","year":"2017","unstructured":"Janda M, Gebski V, Davies LC, Forder P, Brand A, Hogg R, et al. Effect of total laparoscopic hysterectomy vs total abdominal hysterectomy on disease-free survival among women with stage I endometrial cancer. JAMA. 2017;317:1224.","journal-title":"JAMA"},{"key":"582_CR35","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s00432-013-1504-3","volume":"139","author":"Q Lu","year":"2013","unstructured":"Lu Q, Liu H, Liu C, Wang S, Li S, Guo S, et al. Comparison of laparoscopy and laparotomy for management of endometrial carcinoma: a prospective randomized study with 11-year experience. J Cancer Res Clin Oncol. 2013;139:1853\u20139.","journal-title":"J Cancer Res Clin Oncol"},{"key":"582_CR36","doi-asserted-by":"publisher","first-page":"5331","DOI":"10.1200\/JCO.2009.22.3248","volume":"27","author":"JL Walker","year":"2009","unstructured":"Walker JL, Piedmonte MR, Spirtos NM, Eisenkop SM, Schlaerth JB, Mannel RS, et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol. 2009;27:5331\u20136.","journal-title":"J Clin Oncol"},{"key":"582_CR37","unstructured":"Colombo N, Creutzberg C, Amant F, Bosse T, Gonz\u00e1lez-Mart\u00edn A, Ledermann J, et al. ESMO\u2013ESGO\u2013ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Radiother Oncol. Elsevier BV. 2015;117:559\u201381."},{"key":"582_CR38","unstructured":"Palomba S, Falbo A, Mocciaro R, Russo T, Zullo F. Laparoscopic treatment for endometrial cancer: a meta-analysis of randomized controlled trials (RCTs). Gynecol Oncol. Elsevier Inc. 2009;112:415\u201321."},{"key":"582_CR39","unstructured":"Uccella S, Bonzini M, Palomba S, Fanfani F, Malzoni M, Ceccaroni M, et al. Laparoscopic vs. open treatment of endometrial cancer in the elderly and very elderly: an age-stratified multicenter study on 1606 women. Gynecol Oncol. Elsevier B.V. 2016;141:211\u20137."},{"key":"582_CR40","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1245\/s10434-015-5062-6","volume":"23","author":"MM Leitao","year":"2016","unstructured":"Leitao MM, Narain WR, Boccamazzo D, Sioulas V, Cassella D, Ducie JA, et al. Impact of robotic platforms on surgical approach and costs in the management of morbidly obese patients with newly diagnosed uterine cancer. Ann Surg Oncol. 2016;23:2192\u20138.","journal-title":"Ann Surg Oncol"},{"key":"582_CR41","doi-asserted-by":"crossref","unstructured":"M\u00e4enp\u00e4\u00e4 MM, Nieminen K, Tom\u00e1s EI, Laurila M, Luukkaala TH, M\u00e4enp\u00e4\u00e4 JU. Robotic-assisted vs traditional laparoscopic surgery for endometrial cancer: a randomized controlled trial. Am J Obstet Gynecol. Elsevier Inc. 2016;215:588.e1\u20137.","DOI":"10.1016\/j.ajog.2016.06.005"},{"key":"582_CR42","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Frost JA, Webster KE, Bryant A, Morrison J. Lymphadenectomy for the management of endometrial cancer. In: Morrison J, editor. Cochrane Database Syst Rev. Chichester: John Wiley & Sons, Ltd.; 2015. p. 30. Largest meta-analysis about the role of lymph node dissection in endometrial cancer.","DOI":"10.1002\/14651858.CD007585.pub3"},{"key":"582_CR43","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S1470-2045(11)70070-5","volume":"12","author":"M Ballester","year":"2011","unstructured":"Ballester M, Dubernard G, L\u00e9curu F, Heitz D, Mathevet P, Marret H, et al. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). Lancet Oncol. 2011;12:469\u201376.","journal-title":"Lancet Oncol"},{"key":"582_CR44","doi-asserted-by":"crossref","unstructured":"Holloway RW, Abu-Rustum NR, Backes FJ, Boggess JF, Gotlieb WH, Jeffrey Lowery W, et al. Sentinel lymph node mapping and staging in endometrial cancer: a Society of Gynecologic Oncology literature review with consensus recommendations. Gynecol Oncol. Elsevier Inc. 2017.","DOI":"10.1016\/j.ygyno.2017.05.027"},{"key":"582_CR45","unstructured":"Kang S, Yoo HJ, Hwang JH, Lim M-C, Seo S-S, Park S-Y. Sentinel lymph node biopsy in endometrial cancer: meta-analysis of 26 studies. Gynecol Oncol. Elsevier Inc. 2011;123:522\u20137."},{"key":"582_CR46","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ygyno.2008.05.032","volume":"111","author":"AM Perrone","year":"2008","unstructured":"Perrone AM, Casadio P, Formelli G, Levorato M, Ghi T, Costa S, et al. Cervical and hysteroscopic injection for identification of sentinel lymph node in endometrial cancer. Gynecol Oncol. 2008;111:62\u20137.","journal-title":"Gynecol Oncol"},{"key":"582_CR47","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Holloway RW, Abu-Rustum NR, Backes FJ, Boggess JF, Gotlieb WH, Jeffrey Lowery W, et al. Sentinel lymph node mapping and staging in endometrial cancer: a Society of Gynecologic Oncology literature review with consensus recommendations. Gynecol Oncol. Elsevier Inc. 2017;146:405\u201315. Review about different techniques in order to detect SNLD in endometrial cancer.","DOI":"10.1016\/j.ygyno.2017.05.027"},{"key":"582_CR48","doi-asserted-by":"publisher","unstructured":"How J, Gotlieb WH, Press JZ, Abitbol J, Pelmus M, Ferenczy A, et al. Comparing indocyanine green, technetium, and blue dye for sentinel lymph node mapping in endometrial cancer. Gynecol Oncol. Elsevier Inc. 2015;137:436\u201342. \n                      https:\/\/doi.org\/10.1016\/j.ygyno.2015.04.004\n                      \n                    .","DOI":"10.1016\/j.ygyno.2015.04.004"},{"key":"582_CR49","unstructured":"Rossi EC, Kowalski LD, Scalici J, Cantrell L, Schuler K, Hanna RK, et al. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol. Elsevier Ltd. 2017;18:384\u201392."},{"key":"582_CR50","doi-asserted-by":"publisher","first-page":"81","DOI":"10.12688\/f1000research.10020.1","volume":"6","author":"A-Q Tran","year":"2017","unstructured":"Tran A-Q, Gehrig P. Recent Advances in Endometrial Cancer. F1000Res. 2017;6:81 \n                      https:\/\/f1000research.com\/articles\/6-81\/v1\n                      \n                    .","journal-title":"F1000Res"},{"key":"582_CR51","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1245\/s10434-015-4612-2","volume":"23","author":"MB Schiavone","year":"2016","unstructured":"Schiavone MB, Zivanovic O, Zhou Q, Leitao MM, Levine DA, Soslow RA, et al. Survival of patients with uterine carcinosarcoma undergoing sentinel lymph node mapping. Ann Surg Oncol. 2016;23:196\u2013202.","journal-title":"Ann Surg Oncol"},{"key":"582_CR52","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1097\/IGC.0b013e3182954da8","volume":"23","author":"CH Kim","year":"2013","unstructured":"Kim CH, Soslow RA, Park KJ, Barber EL, Khoury-Collado F, Barlin JN, et al. Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging. Int J Gynecol Cancer. 2013;23:964\u201370.","journal-title":"Int J Gynecol Cancer"},{"key":"582_CR53","doi-asserted-by":"crossref","unstructured":"Zhou M, Wang X, Jiang L, Chen X, Bao X, Chen X. The diagnostic value of one step nucleic acid amplification (OSNA) in differentiating lymph node metastasis of tumors: a systematic review and meta-analysis. Int J Surg IJS Publishing Group Ltd. 2018;56:49\u201356.","DOI":"10.1016\/j.ijsu.2018.05.010"},{"key":"582_CR54","unstructured":"L\u00f3pez-Ruiz ME, Diestro MD, Y\u00e9benes L, Berj\u00f3n A. D\u00edaz de la Noval B, Mendiola M, et al. One-step nucleic acid amplification (OSNA) for the detection of sentinel lymph node metastasis in endometrial cancer. Gynecol Oncol. Elsevier Inc. 2016;143:54\u20139."},{"key":"582_CR55","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1245\/s10434-014-4038-2","volume":"22","author":"T Nagai","year":"2015","unstructured":"Nagai T, Niikura H, Okamoto S, Nakabayashi K, Matoda M, Utsunomiya H, et al. A new diagnostic method for rapid detection of lymph node metastases using a one-step nucleic acid amplification (OSNA) assay in endometrial cancer. Ann Surg Oncol. 2015;22:980\u20136.","journal-title":"Ann Surg Oncol"},{"key":"582_CR56","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/annonc\/mdv484","volume":"27","author":"N Colombo","year":"2016","unstructured":"Colombo N, Creutzberg C, Amant F, Bosse T, Gonz\u00e1lez-Mart\u00edn A, Ledermann J, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016;27:16\u201341.","journal-title":"Ann Oncol"},{"key":"582_CR57","doi-asserted-by":"crossref","unstructured":"Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma: more than two types. Lancet Oncol. Elsevier Ltd. 2014;15:e268\u201378.","DOI":"10.1016\/S1470-2045(13)70591-6"},{"key":"582_CR58","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"A Bois Du","year":"2009","unstructured":"Du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzin. Cancer. 2009;115:1234\u201344.","journal-title":"Cancer"},{"key":"582_CR59","unstructured":"Heitz F, Harter P, Alesina PF, Walz MK, Lorenz D, Groeben H, et al. Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery. Gynecol Oncol. Elsevier Inc. 2016;141:264\u201370."},{"key":"582_CR60","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ygyno.2006.10.037","volume":"104","author":"EL Eisenhauer","year":"2007","unstructured":"Eisenhauer EL, Chi DS. Liver mobilization and diaphragm peritonectomy\/resection. Gynecol Oncol. 2007;104:25\u20138.","journal-title":"Gynecol Oncol"},{"key":"582_CR61","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.ygyno.2004.01.029","volume":"94","author":"DS Chi","year":"2004","unstructured":"Chi DS, Franklin CC, Levine DA, Akselrod F, Sabbatini P, Jarnagin WR, et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol. 2004;94:650\u20134.","journal-title":"Gynecol Oncol"},{"key":"582_CR62","unstructured":"Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. Elsevier Inc. 2009;114:26\u201331."},{"key":"582_CR63","doi-asserted-by":"publisher","unstructured":"Martinez A, Pomel C, Mery E, Querleu D, Gladieff L, Ferron G. Celiac lymph node resection and porta hepatis disease resection in advanced or recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol. Elsevier Inc. 2011;121:258\u201363. \n                      https:\/\/doi.org\/10.1016\/j.ygyno.2010.12.328\n                      \n                    .","DOI":"10.1016\/j.ygyno.2010.12.328"},{"key":"582_CR64","doi-asserted-by":"publisher","unstructured":"Prader S, Harter P, Grimm C, Traut A, Waltering KU, Alesina PF, et al. Surgical management of cardiophrenic lymph nodes in patients with advanced ovarian cancer. Gynecol Oncol. Elsevier B.V. 2016;141:271\u20135. \n                      https:\/\/doi.org\/10.1016\/j.ygyno.2016.03.012\n                      \n                    .","DOI":"10.1016\/j.ygyno.2016.03.012"},{"key":"582_CR65","unstructured":"Mert I, Kumar A, Sheedy SP, Weaver AL, McGree ME, Kim B, et al. Clinical significance of enlarged cardiophrenic lymph nodes in advanced ovarian cancer: implications for survival. Gynecol Oncol. Elsevier Inc. 2018;148:68\u201373."},{"key":"582_CR66","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1038\/sj.bjc.6603803","volume":"96","author":"JK Chan","year":"2007","unstructured":"Chan JK, Urban R, Hu JM, Shin JY, Husain A, Teng NN, et al. The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13,918 patients. Br J Cancer. 2007;96:1817\u201322.","journal-title":"Br J Cancer"},{"key":"582_CR67","doi-asserted-by":"publisher","first-page":"5500","DOI":"10.1200\/JCO.2017.35.15_suppl.5500","volume":"35","author":"P Harter","year":"2017","unstructured":"Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, et al. LION: Lymphadenectomy in ovarian neoplasms\u2014a prospective randomized AGO study group led gynecologic cancer intergroup trial. J Clin Oncol. 2017;35:5500.","journal-title":"J Clin Oncol"},{"key":"582_CR68","unstructured":"Ataseven B, Grimm C, Harter P, Prader S, Traut A, Heitz F, et al. Prognostic value of lymph node ratio in patients with advanced epithelial ovarian cancer. Gynecol Oncol. Elsevier Inc. 2014;135:435\u201340."},{"key":"582_CR69","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.2217\/fon-2017-0292","volume":"13","author":"D Atallah","year":"2017","unstructured":"Atallah D, El Rassy E, Chahine G. Is the LION strong enough? Future Oncol. 2017;13:1835\u20137.","journal-title":"Future Oncol"},{"key":"582_CR70","unstructured":"Chang SJ, Hodeib M, Chang J, Bristow RE. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol. Elsevier Inc. 2013;130:493\u20138."},{"key":"582_CR71","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Dahm-k\u00e4hler P, Palmqvist C, Staf C, Holmberg E, Johannesson L. Gynecologic oncology centralized primary care of advanced ovarian cancer improves complete cytoreduction and survival\u2014a population-based cohort study. Gynecol Oncol. Elsevier Inc. 2016;142:211\u20136. Retrospective study showing the importance of cancer centralization.","DOI":"10.1016\/j.ygyno.2016.05.025"},{"key":"582_CR72","doi-asserted-by":"crossref","unstructured":"Bristow BRE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era. 2002;20:1248\u201359.","DOI":"10.1200\/JCO.2002.20.5.1248"},{"key":"582_CR73","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH. Surgical responsibilities in the management of peritoneal carcinomatosis. 2010;713\u201324.","DOI":"10.1002\/jso.21484"},{"key":"582_CR74","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1245\/ASO.2006.08.021","volume":"13","author":"A Fagotti","year":"2006","unstructured":"Fagotti A, Ferrandina G, Fanfani F, Ercoli A, Lorusso D, Rossi M, et al. A Laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol. 2006;13:1156\u201361.","journal-title":"Ann Surg Oncol"},{"key":"582_CR75","doi-asserted-by":"crossref","unstructured":"Petrillo M, Vizzielli G, Fanfani F, Gallotta V, Cosentino F, Chiantera V, et al. Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: proof of a concept 272 enrolled pts. 234 eligible pts. receiving S-LPS followed by. Gynecol Oncol. Elsevier Inc. 2015;5\u20139.","DOI":"10.1016\/j.ygyno.2015.01.006"},{"key":"582_CR76","unstructured":"Gupta R, Gan TJ. Preoperative nutrition and prehabilitation. Anesthesiol Clin. Elsevier Inc. 2016;34:143\u201353."},{"key":"582_CR77","unstructured":"Spratt JS, Adcock RA, Muskovin M, Sherrill W, Mckeown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. 1980;40:256\u201360."},{"key":"582_CR78","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S1470-2045(05)70539-8","volume":"7","author":"PH Sugarbaker","year":"2006","unstructured":"Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 2006;7:69\u201376.","journal-title":"Lancet Oncol"},{"key":"582_CR79","doi-asserted-by":"publisher","first-page":"236","DOI":"10.21037\/atm.2017.03.96","volume":"5","author":"J Kim","year":"2017","unstructured":"Kim J, Bhagwandin S, Labow DM. Malignant peritoneal mesothelioma: a review. Ann Transl Med. 2017;5:236.","journal-title":"Ann Transl Med"},{"key":"582_CR80","doi-asserted-by":"publisher","first-page":"72","DOI":"10.21037\/jgo.2016.03.07","volume":"7","author":"J Esquivel","year":"2016","unstructured":"Esquivel J. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: survival outcomes and patient selection. J Gastrointest Oncol. 2016;7:72\u20138.","journal-title":"J Gastrointest Oncol"},{"key":"582_CR81","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1245\/s10434-017-6151-5","volume":"24","author":"TP Batista","year":"2017","unstructured":"Batista TP. Comment on: Surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg OncolSpringer International Publishing. 2017;24:630.","journal-title":"Ann Surg Oncol"},{"key":"582_CR82","unstructured":"Chiva LM, Gonzalez-Martin A. A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer. Gynecol Oncol. Elsevier Inc. 2015;136:130\u20135."},{"key":"582_CR83","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ Driel van","year":"2018","unstructured":"\u2022\u2022 van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, HWR S, RHM H, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378:230\u201340 Clinical trial of HIPEC in ovarian cancer.","journal-title":"N Engl J Med"},{"key":"582_CR84","doi-asserted-by":"crossref","unstructured":"Fotopoulou C, Sehouli J, Mahner S, Harter P, Van Nieuwenhuysen E, Gonzalez-Martin A, et al. HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer? Ann Oncol. 2018;1\u201314.","DOI":"10.1093\/annonc\/mdy198"},{"key":"582_CR85","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","volume":"335","author":"DS Alberts","year":"1996","unstructured":"Alberts DS, Liu PY, Hannigan EV, O\u2019Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950\u20135.","journal-title":"N Engl J Med"},{"key":"582_CR86","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"M Markman","year":"2001","unstructured":"Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the gynecologic oncology group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001\u20137.","journal-title":"J Clin Oncol"},{"key":"582_CR87","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. GOG 172 Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34\u201343.","journal-title":"N Engl J Med"},{"key":"582_CR88","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3802\/jgo.2012.23.2.75","volume":"23","author":"K Fujiwara","year":"2012","unstructured":"Fujiwara K. Three ongoing intraperitoneal chemotherapy trials in ovarian cancer. J Gynecol Oncol. 2012;23:75\u20137.","journal-title":"J Gynecol Oncol"},{"key":"582_CR89","doi-asserted-by":"publisher","first-page":"viii40","DOI":"10.1093\/annonc\/mdx451","volume":"28","author":"BJ Monk","year":"2017","unstructured":"Monk BJ, Chan JK. Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer? Ann Oncol. 2017;28:viii40\u20135.","journal-title":"Ann Oncol"},{"key":"582_CR90","unstructured":"\u2022\u2022 Walker J, Brady M, Di Silvestro P. A phase III clinical trial of bevacizumab with IV versus IP chemotherapy in ovarian, fallopian tube, and primary peritoneal carcinoma: a GOG\/NRG trial (GOG 252). 2016. Society of Gynecologic Oncology Annual Meeting on Women\u2019s Cancer. Abstract 6. Outcomes of intraperitoneal chemotherapy in ovarian cancer."},{"key":"582_CR91","doi-asserted-by":"crossref","unstructured":"Mirza MR, Pignata S, Ledermann JA. Latest clinical evidence and further development of PARP inhibitors in ovarian cancer. Ann Oncol. 2018.","DOI":"10.1093\/annonc\/mdy174"},{"key":"582_CR92","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","volume":"13","author":"P Harter","year":"2006","unstructured":"Harter P, Du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13:1702\u201310.","journal-title":"Ann Surg Oncol"},{"key":"582_CR93","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/IGC.0b013e31820aaafd","volume":"21","author":"P Harter","year":"2011","unstructured":"Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the multicenter intergroup study DESKTOP II. A project of the AGO kommission OVAR, AGO study group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer. 2011;21:289\u201395.","journal-title":"Int J Gynecol Cancer"},{"key":"582_CR94","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1200\/JCO.2017.35.15_suppl.5501","volume":"35","author":"A Bois Du","year":"2017","unstructured":"\u2022\u2022 Du Bois A, Vergote I, Ferron G, Reuss A, Meier W, Greggi S, et al. Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III\/ENGOT ov20. J Clin Oncol. 2017;35:5501 Role of surgery in ovarian cancer recurrence.","journal-title":"J Clin Oncol"},{"key":"582_CR95","doi-asserted-by":"crossref","unstructured":"Bommert M, Harter P, Heitz F, du Bois A. When should surgery be used for recurrent ovarian carcinoma? Clin Oncol. Elsevier Ltd. 2018;1\u20135.","DOI":"10.1016\/j.clon.2018.04.006"},{"key":"582_CR96","doi-asserted-by":"crossref","unstructured":"Bristow RE, Chang J, Ziogas A, Randall LM, Anton-culver H. Gynecologic oncology high-volume ovarian cancer care: survival impact and disparities in access for advanced-stage disease. Gynecol Oncol. Elsevier Inc. 2013.","DOI":"10.1016\/j.ygyno.2013.12.017"},{"key":"582_CR97","unstructured":"Ling Y, Kyrgiou M, Bryant A, Everett T, Dickinson HO. Centralisation of services for gynecological cancers\u2014a Cochrane systematic review. Gynecol Oncol. Elsevier Inc. 2012;126:286\u201390."},{"key":"582_CR98","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1093\/annonc\/mdt237","volume":"24","author":"D Querleu","year":"2013","unstructured":"Querleu D, Ray-Coquard I, Classe JM, Aucouturier JS, Bonnet F, Bonnier P, et al. Quality indicators in ovarian cancer surgery: report from the French Society of Gynecologic Oncology (Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Oncologie Gyn\u00e9cologique, SFOG). Ann Oncol. 2013;24:2732\u20139.","journal-title":"Ann Oncol"},{"key":"582_CR99","unstructured":"Harter P, Muallem ZM, Buhrmann C, Lorenz D, Kaub C, Hils R, et al. Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. Gynecol Oncol. Elsevier Inc. 2011;121:615\u20139."}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-018-0582-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-018-0582-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-018-0582-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,9]],"date-time":"2019-11-09T00:18:52Z","timestamp":1573258732000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-018-0582-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,9]]},"references-count":99,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["582"],"URL":"https:\/\/doi.org\/10.1007\/s11864-018-0582-5","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,9]]},"assertion":[{"value":"9 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Martina Aida Angeles declares that she has no conflict of interest.Carlos Mart\u00ednez-G\u00f3mez declares that he has no conflict of interest.Federico Migliorelli declares that he has no conflict of interest.Marie Voglimacci declares that she has no conflict of interest.Justine Figurelli declares that she has no conflict of interest.Stephanie Motton has received research funding from Intuitive Surgical, Inc. and has also received compensation from Intuitive Surgical, Inc. for service as a consultant.Yann Tanguy Le Gac declares that he has no conflict of interest.Gw\u00e9na\u00ebl Ferron declares that she has no conflict of interest.Alejandra Martinez declares that she has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"73"}}